SARA test results for different types of asphalt. by Yi Wang (32470)

Subjects: “…diffusion coefficients increased…”

Economic evaluation of the process. by Fabrizio Schettini (12009517)

Subjects:

Budget impact analysis. by Fabrizio Schettini (12009517)

Subjects:

Effectiveness indicators. by Fabrizio Schettini (12009517)

Subjects:

Regression model for costs. by Fabrizio Schettini (12009517)

Subjects:

A focus on the development of adverse events. by Fabrizio Schettini (12009517)

Subjects:

S1 Data - by Fabrizio Schettini (12009517)

Subjects:

Regression models for effectiveness. by Fabrizio Schettini (12009517)

Subjects:

Description of the sample under assessment. by Fabrizio Schettini (12009517)

Subjects:

Value priorities over time and by gender with no significant differences. by Christian Hannes (17817132)

Significantly Increased Specific Discharge Capacitance at Carbon Fibers Created via Architected Ultramicropores by Ying Zheng (170527)

Significantly Increased Specific Discharge Capacitance at Carbon Fibers Created via Architected Ultramicropores by Ying Zheng (170527)

Significantly Increased Specific Discharge Capacitance at Carbon Fibers Created via Architected Ultramicropores by Ying Zheng (170527)

Significantly Increased Specific Discharge Capacitance at Carbon Fibers Created via Architected Ultramicropores by Ying Zheng (170527)

T lymphocyte populations significantly increased in APRIL^-/-/BLyS^-/- group. by Natalie M. Bath (6316517)

Subjects:

CD4+CD8+ double positive T cells significantly increase at day 30 following IR. by Jordan A. Gunning (18143970)

IGF-1 injections significantly attenuate the increase in macrophages and neutrophils observed at day 30 following IR. by Jordan A. Gunning (18143970)

Regenerating axons are increased by ATRA and decreased by clodronate. by Valeria De La Rosa-Reyes (6658613)

“…Compared to PBS-treated, the number of regenerating axons is doubled by ATRA treatment, decreased by 30% by clodronate, and, in the case of ATRA combined with clodronate, is not significantly different.…”

DAF-16/FOXO is Required for Locomotory Healthspan and Lifespan Benefits of Genetic Glycolysis Disruption. by Brian Onken (86790)

“…The beneficial effects of glycolytic gene disruptions seen in wild-type animals (refer to <a href="http://www.plosgenetics.org/article/info:doi/10.1371/journal.pgen.1008982#pgen.1008982.g001" target="_blank">Fig 1D</a>) are mostly eliminated in the <i>daf-16</i> mutant background: median survival is not increased in <i>daf-16</i> animals treated with either RNAi, and the survival curve of <i>daf-16</i> mutants raised on <i>pyk-2(RNAi)</i> is not significantly (n.s.) different than controls (Log-rank test). …”

Analysis of Significantly Different ARGs and Resistance Mechanisms. by Xu Jia (187142)